Drug Name: Jaypirca
Indications: To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
Active Ingredient: Pirtobrutinib
Company: Eli Lilly and Company
Approval Date: 1/27/2023
More Details: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf